Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations - Ciccioli, Mariacristina; Kim, Kyukwang; Khazan , Negar; Khoury, Joseph D; Cooke, Martin J; Miller, M Craig; O’Shannessy, Daniel J; Pailhes-Jimenez, Anne-Sophie; Moore, Richard G (Journal of experimental & clinical cancer research, 2024)
Keywords: Adult; Aged; Aged, 80 and over; Approximation; Biomarkers, Tumor - blood; Biopsy; Blood; Body fluids; Breast cancer; Breast Neoplasms - blood; Breast Neoplasms - pathology; Cancer therapies; Cell Separation - methods; Cellular biology; CFR; Circulating tumor cells; Federal regulation; Female; Females; Fluorescent Antibody Technique; Humans; Informed consent; Liquid biopsy; Metastasis; Metastatic breast cancer; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating - metabolism; Neoplastic Cells, Circulating - pathology; Parsortix® PC1 system; Sample size; Tumors; United States; United States Food and Drug Administration; United States; United States--US; Parsortix® PC1 system; Liquid biopsy; Metastatic breast cancer; Circulating tumor cells